Xilio Therapeutics Inc (NAS:XLO)
$ 1.02 -0.02 (-1.92%) Market Cap: 44.84 Mil Enterprise Value: -7.13 Mil PE Ratio: 0 PB Ratio: 2.18 GF Score: 27/100

Xilio Therapeutics Inc Pipeline Progress and SITC Update Transcript

Nov 06, 2023 / 01:00PM GMT
Release Date Price: $2.16 (-10.00%)
Operator

Good morning, and welcome to the Xilio Therapeutics conference call. (Operator Instructions) Please be advised that this call is being recorded. At this time, I would like to turn the call over to your host, Stacey Davis at Xilio Therapeutics.

Stacey Davis Xilio Therapeutics
Inc. - Chief Business Officer

Good morning, everyone. I'm Stacey Davis, Chief Business Officer of Xilio Therapeutics, and I'd like to welcome you all to our pipeline progress and SITC update call. Today, we'll be reviewing progress across our clinical pipeline, including the initial Phase 1/2 clinical data presented at SITC last week for XTX202, our tumor-activated engineered, beta-gamma IL-2.

On Friday, we issued a press release announcing the XTX202 data reported at SITC. You can access the press release and slides from today's presentation by going to the Investors and Media section of our corporate website.

Before we get started, I'd like to remind everyone that the statements we make on this conference call will include forward-looking statements. Actual events or

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot